Health Policy and Technology最新文献

{"title":"Translating innovative medical devices from prototype to practice: A Delphi study of urgent financial barriers and promising solutions","authors":"Sanne Allers ,&nbsp;Frank Eijkenaar ,&nbsp;Frederik T. Schut ,&nbsp;Erik M. van Raaij","doi":"10.1016/j.hlpt.2024.100964","DOIUrl":"10.1016/j.hlpt.2024.100964","url":null,"abstract":"<div><h3>Objectives</h3><div>Financial barriers are widely perceived as a major obstacle for translating innovative medical devices from prototype to practice. However, a clear overview of relevant financial barriers, their perceived urgency, and promising solutions is lacking. Therefore, this study aims to identify and prioritize the multitude of barriers and solutions from the perspective of various stakeholders involved in the development and financing of innovative medical devices.</div></div><div><h3>Methods</h3><div>We performed a Delphi study with three consecutive questionnaires sent to 72 experts from five stakeholder groups in the Netherlands: innovators, (social) venture capital investors, health insurers, healthcare providers, and (semi)governmental agencies.</div></div><div><h3>Results</h3><div>The response rate was 71 % in the first round and decreased to 46 % in the third round, with each stakeholder group being well-represented. We identified 33 distinctive barriers and 183 associated solutions. Although respondents assigned a consistently high priority to each of these barriers, eight barriers stand out in terms of high priority and degree of consensus. In addition, 22 solutions were considered most promising to solve these barriers. For both the barriers and the solutions, differences in the degree of consensus were larger within than between stakeholder groups.</div></div><div><h3>Conclusions</h3><div>Our study has identified and prioritized a diverse set of financial and related challenges and potential solutions to translate innovative medical devices, as jointly faced by the stakeholders. Improvement efforts should first focus on addressing the consistently high-priority barriers, using the solutions perceived as being most suitable.</div></div><div><h3>Public interest summary</h3><div>To progress from an innovative prototype to a medical device in practice, products must be able to pass through a critical phase in the innovation process. This phase is called the valley of death, because a lack of financial opportunities kills many innovative technologies at this stage. The present study provides insight into the multitude of financial barriers that play a role in this innovation phase, and the priorities assigned to these barriers by various groups of relevant stakeholders. In addition, stakeholders were asked to suggest promising solutions to address these barriers. Consequently, this study has shown the prioritized need for financial support of a co-creation process of innovations between innovators and users. In addition, the stakeholders provided suitable solutions focusing on timely communication, alternative payment models, and disincentivizing low-value care. Finally, opinions strongly diverged about solutions that require radical changes towards a more centrally governed innovation system.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100964"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Internet use and satisfaction with overall medical services among older adults in China: Counterfactual estimation based on propensity score matching","authors":"Lei Wu,&nbsp;Feng Zhao,&nbsp;Cherong Chen","doi":"10.1016/j.hlpt.2024.100954","DOIUrl":"10.1016/j.hlpt.2024.100954","url":null,"abstract":"<div><h3>Objectives</h3><div>In the context of China's \"Internet Plus Healthcare\" reform, this study aims to test whether the use of the Internet has improved older adults’ satisfaction with overall medical services (SMS), and analyze the effectiveness of the reform in the older population.</div></div><div><h3>Methods</h3><div>Based on the cross-sectional data from the China Family Panel Studies in 2020, propensity score matching (PSM) models were employed to examine the relationship between Internet use and SMS of Chinese older adults (4661 observations aged 60 and above), and ordinary least square (OLS) regression models were adopted to explore the mediating role of self-rated health (SH) in this relationship.</div></div><div><h3>Results</h3><div>Internet use was associated with a decline in SMS among older adults in China, with Internet users’ SMS being about 18 % lower than non-users. However, we found no evidence for SH mediating the relationship between Internet use and SMS, which is contrary to our expectation.</div></div><div><h3>Conclusions</h3><div>Internet use has led to lower levels of SMS among Chinese older adults. In the future, the government needs to further promote the achievements of the “Internet Plus Healthcare” reform to benefit senior citizens more equitably and ultimately improve their SMS.</div></div><div><h3>Public interest summary</h3><div>This research showed that Internet use has led to a decrease in satisfaction with overall medical services (SMS) among older adults in China. This result could assist decision-makers in better understanding the healthcare reform achievement and how to further expand the effectiveness of health governance.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100954"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The business case for palliative care: Translating research into program development in low- and middle-income countries (LMICs)","authors":"Arun Ghoshal","doi":"10.1016/j.hlpt.2024.100965","DOIUrl":"10.1016/j.hlpt.2024.100965","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Scientific abstract&lt;/h3&gt;&lt;div&gt;The provision of palliative care is a critical component of comprehensive healthcare, particularly for individuals facing life-limiting illnesses. While the importance of palliative care has been recognized in high-income countries, its integration and implementation in low- and middle-income countries (LMICs) pose unique challenges. In LMICs, limited resources, competing health priorities, and cultural factors have historically hindered the development and delivery of palliative care services. However, recent research has demonstrated the numerous benefits of palliative care, including improved patient outcomes, enhanced quality of life, and cost-effectiveness.&lt;/div&gt;&lt;div&gt;A multifaceted approach is needed to develop palliative care programs in LMICs successfully. Firstly, there is a need to raise awareness among policymakers, healthcare providers, and the public about the value and benefits of palliative care. This can be achieved through targeted advocacy campaigns, capacity-building initiatives, and knowledge dissemination. Secondly, program development should be context-specific and tailored to the unique challenges and resources of each LMIC. This includes establishing partnerships with local healthcare providers, integrating palliative care into existing healthcare systems, and developing culturally sensitive models of care. Furthermore, financing mechanisms and sustainable funding sources must be explored to ensure the long-term viability of palliative care programs. This may involve advocating for the integration of palliative care into national health policies, exploring innovative financing models, and leveraging international partnerships and funding opportunities.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Public interest abstract&lt;/h3&gt;&lt;div&gt;The global community has recognized that palliative care is integral to both universal health coverage and the right to health and helps improve the quality of life for people with serious illnesses as well as their caregivers/families. While it is well-established in wealthier countries, implementing palliative care in low- and middle-income countries (LMICs) is challenging. In LMICs, limited resources have made it difficult to provide palliative care. However, recent research shows that palliative care brings many benefits, such as better patient outcomes and cost-effectiveness. These findings make a strong case for expanding palliative care in LMICs. To make this happen, there is a need to raise awareness about the value of palliative care among policymakers, healthcare providers, and the public. We must also develop tailored programs that consider each country's unique challenges and resources. Finding sustainable funding sources is crucial, which may involve integrating palliative care into national health policies and seeking international partnerships. By embracing palliative care, LMICs can improve the lives of those with serious illnesses, strengthen their healthcare systems, ","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100965"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taiwanese healthcare providers’ attitudes regarding reprocessing and reuse of single-use devices","authors":"Chiu-Hsiang Lee ,&nbsp;Mohsen Saffari ,&nbsp;Hsiu-Tzy Chiang ,&nbsp;Jung-Sheng Chen ,&nbsp;Jiun-Ting Wu ,&nbsp;Wai Chuen Poon ,&nbsp;Marc N. Potenza ,&nbsp;Chung-Ying Lin","doi":"10.1016/j.hlpt.2024.100969","DOIUrl":"10.1016/j.hlpt.2024.100969","url":null,"abstract":"<div><h3>Objectives</h3><div>Reusing medical single-use devices (SUDs) has been increasing worldwide. However, there is limited understanding regarding healthcare workers’ perceptions of SUD standards and regulations. The study examined knowledge of and attitudes towards SUDs in Taiwanese healthcare providers.</div></div><div><h3>Methods</h3><div>Overall, 900 healthcare providers from 20 cities/counties in Taiwan participated in a nationwide cross-sectional study. A questionnaire based on recommendations from the Infection Control Society of Taiwan was developed and it demonstrated good psychometric properties (Cronbach's alpha= 0.66-90). The questionnaire assessed SUD-related knowledge, opinions, institutional/administrative policies, quality control, and institutional safety procedures. Linear regression models investigated associations of SUD-related factors with participant characteristics.</div></div><div><h3>Results</h3><div>Although most participants (90 %) knew that unprocessed SUDs should not be reused and may threaten patients, approximately half supported SUD reuse and were confident that their institutions could reprocess SUDs. Almost all participants (&gt;95 %) supported standard protocols for reprocessing of SUDs. Institution type (medical center vs. regional/district hospitals) and work experience related to views on SUD reuse/reprocessing (p&lt;0.05).</div></div><div><h3>Conclusions</h3><div>Despite positive attitudes of Taiwanese healthcare workers toward SUD reprocessing/reuse, many did not have adequate knowledge regarding current standards/regulations in their worksite. Designing interventions to promote Taiwanese healthcare workers' awareness of the common regulations or guidelines related to SUDs reprocessing/reuse is suggested.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100969"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does price negotiation in China bring high-value novel drugs to the national medical insurance beneficiaries?","authors":"Xingyue Zhu ,&nbsp;Yang Chen","doi":"10.1016/j.hlpt.2024.100963","DOIUrl":"10.1016/j.hlpt.2024.100963","url":null,"abstract":"<div><h3>Objective</h3><div>China has initiated the drug price negotiation since 2017 to incorporate in-patent drugs into the reimbursement list of the Basic Medical Insurance (BMI). From 2020 onwards, the annual price negotiation accepts unsolicited applications from drug companies. However, it's unknown whether the negotiations attract new drugs with higher clinical benefits to improve the allocative efficiency of the BMI.</div></div><div><h3>Method</h3><div>We collected the new oncology indications approved in China between Jan 1, 2015 and June 30, 2023, and checked their reimbursement status in the recent four negotiations (2020–2023). The clinical benefits were defined as the treatment effects on the primary outcome in the pivotal trial supporting the indication approval. The outcomes were classified as response rate, time-to-event, and overall survival. An instrument variables (IV) strategy was established to explore the association between the reimbursement status and the magnitude of clinical benefits for each outcome type.</div></div><div><h3>Results</h3><div>A total of 222 oncology indications were gathered, among which 60.4 % obtained the reimbursement eligibility through the price negotiations. The IV regressions found that, the reimbursed indications had a 20 % higher response rate and a 0.26 lower hazard ratio of incurring a specific event than the non-reimbursed; but the survival benefits didn't differ between the two groups.</div></div><div><h3>Conclusion</h3><div>The price negotiations in China have brought new drugs with higher surrogate benefits into the BMI, yet have not attracted those with superior survival benefits. Regulatory innovations are needed to prioritize drugs validating therapeutic value in the reimbursement decision-making process to refine drug access.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100963"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of transferred costs in economic evaluations from the Middle East North Africa Region","authors":"Meriem Fgaier ,&nbsp;Hana Al-Abdulkarim ,&nbsp;Hossein Motahari-Nezhad ,&nbsp;Nhlanhlayakhe Nkwanyana ,&nbsp;Prof. Márta Péntek ,&nbsp;Prof. László Gulácsi ,&nbsp;Dr Zsombor Zrubka","doi":"10.1016/j.hlpt.2025.100975","DOIUrl":"10.1016/j.hlpt.2025.100975","url":null,"abstract":"<div><h3>Objectives</h3><div>The Middle East and North Africa (MENA) region is striving to provide their populations with quality healthcare. The challenge for MENA countries is aggravated by the scarcity of health-related cost data which strains their health systems and puts pressure on decision-makers to efficiently allocate resources. Transferring costs from another setting might be a suitable solution to ease the resulting pressure. This paper aims to identify literature utilizing regionally transferred costs and to evaluate their methodology and reporting quality.</div></div><div><h3>Methods</h3><div>Literature search was performed in June 2022 to identify health economic evaluations which reported transferred costs from other jurisdictions between January 2000 and May 2022. Studies selection and data extraction were performed in duplicates. The Consolidated Health Economic Evaluation Reporting Standards 2022 and the Fukuda transparency categorization were used to evaluate the quality of the extracted costs.</div></div><div><h3>Results</h3><div>104 costs were examined from 13 studies. Cost transferability is a recent practice in the region with a slight lead of Gulf Council countries. The majority of donor costs were of poor quality and the selection of donor and destination countries was often poorly justified.</div></div><div><h3>Conclusions</h3><div>The applied methodology was heterogenous and authors have not referred to available international transferability guidelines. We propose a preliminary checklist for structured evaluation of cost-transfer methods to improve reporting tranparency and advance evidence-based health policy making in MENA.</div></div><div><h3>Plain summary</h3><div>The Middle East and North Africa region (MENA) is under significant challenge to implement health technology assessment practice following the scarcity of locally collected economic data. This systematic review explores the transferability of health-related costs as a potential solution to the scarcity of local cost data in the region. 13 studies which reported using 104 transferred costs from MENA countries were included in the final analysis. We concluded that cost transferability practice is recently adopted within MENA, and Golf region is slightly leading with 7 studies transferring over half of the included costs to Golf countries settings. No standard methodologies and references were reported by authors when transferring these costs and both reporting and selection criteria between donor and destination costs and countries were mostly of poor quality and often not justified. We propose a preliminary checklist for structured evaluation of cost transfer methods to improve reporting transparency and advance evidence-based health policy making in MENA.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100975"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of price transparency policies for healthcare services in the United States: A systematic review","authors":"John C. Lin ,&nbsp;Julia S. Gillette ,&nbsp;Angela S. Zhu ,&nbsp;Dustin D. French ,&nbsp;Margaret Weir ,&nbsp;David J. Meyers ,&nbsp;Paul B. Greenberg","doi":"10.1016/j.hlpt.2025.100973","DOIUrl":"10.1016/j.hlpt.2025.100973","url":null,"abstract":"<div><h3>Background</h3><div>This systematic review evaluates the role of price transparency policies for healthcare services in influencing price availability, price awareness, and health costs in the US.</div></div><div><h3>Methods</h3><div>We searched five databases for English-language studies evaluating price transparency policies in the US; literature reviews, perspectives, case reports, non-healthcare studies, and non-US studies were excluded. Two investigators independently conducted data extraction and quality assessment. We examined study risk of bias and quality using Cochrane and National Heart, Lung, and Blood Institute tools, qualitatively summarized study findings, and quantitatively analyzed included studies.</div></div><div><h3>Results</h3><div>Eighty-seven studies were included. Hospital price transparency mandates faced early issues with low compliance. Government price transparency programs were associated with reduced price growth for some services, but many lacked comprehensive pricing data by payer and provider. These findings were limited by the low quality of included studies.</div></div><div><h3>Conclusions</h3><div>Existing price transparency policies appear subject to substantial limitations, although emerging evidence suggests that they hold promise for changing price growth and healthcare utilization. Policymakers should consider modifying price transparency policies to become more robust, accurate, and user-friendly.</div></div><div><h3>Public Interest Summary</h3><div>In a recent review of 87 scientific studies, we investigated the efficacy of US policies in making healthcare prices clear and accessible to the public. Although hospitals often struggled with providing accurate and easy-to-use price information, government programs that shared this information helped slow down the rise in prices and encouraged people to use more affordable healthcare, especially for medical imaging. As healthcare prices keep rising, our findings suggest that better-designed government programs could help make prices clearer for everyone, potentially saving money and helping patients make informed decisions.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100973"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resilience in public health: What is and what should never be","authors":"Alessandro Jatobá","doi":"10.1016/j.hlpt.2025.100974","DOIUrl":"10.1016/j.hlpt.2025.100974","url":null,"abstract":"","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100974"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transforming healthcare system: Outcomes of Healthier-SG from a large tertiary-care hospital in Singapore","authors":"Yong Yang ,&nbsp;Indumathi Venkatachalam ,&nbsp;Chi Ting Low ,&nbsp;Mabel Zhi Qi Foo ,&nbsp;May Kyawt Aung ,&nbsp;Shawn Wee Jin See ,&nbsp;Myat Oo Aung ,&nbsp;Darius Yak Weng Chan ,&nbsp;Shalvi Arora ,&nbsp;Jean Xiang Ying Sim ,&nbsp;Yuke Tien Fong ,&nbsp;Vui Kian Ho ,&nbsp;Yee Sien Ng ,&nbsp;Lian Leng Low ,&nbsp;Srinath Sridharan ,&nbsp;Moi Lin Ling ,&nbsp;Chai Rick Soh","doi":"10.1016/j.hlpt.2024.100968","DOIUrl":"10.1016/j.hlpt.2024.100968","url":null,"abstract":"<div><h3>Objective</h3><div>Healthier-SG is a major transformation of the healthcare system which focuses on proactively preventing individuals from falling ill. We aimed to determine if the introduction of Healthier-SG was associated with changes in outcomes of admitted patients.</div></div><div><h3>Methods</h3><div>Retrospective cohort study of patients aged ≥21 who were admitted 18 months prior to (January 2022 to June 2023) and 6 months post (Jul to Dec 2023) implementation of Healthier-SG. Relevant patient information was also extracted.</div></div><div><h3>Results</h3><div>109,451 inpatients were included overtime with 30,692 (28.0 %) patients admitted post Healthier-SG. For medical conditions that could be managed in the community, admissions for dementia (0.2 % vs. 0.1 % <em>P</em> = 0.003) and peripheral vascular disease (0.4 % vs. 0.3 % <em>P</em> = 0.011) decreased significantly after Healthier-SG, but no differences for most other conditions (all <em>p</em> &gt; 0.05). The patient's hospital length of stay [HLOS, geometric means (GM), prior to 3.8 vs. post Healthier-SG 3.5 days] and in-hospital mortality (3.7 % vs. 2.9 %, all <em>P</em> &lt; 0.001) were significantly decreased post Healthier-SG. The bed-days for patients enrolled with SingHealth cluster (GM, 4.92 vs. 4.77 days, <em>p</em> = 0.022) over 2023 were also decreased after Healthier-SG. Multivariate regression analysis showed implementation of Healthier-SG was associated with statistically significant changes in HLOS [incidence rate ratio (IRR) 0.9, <em>p</em> &lt; 0.001) and in-hospital mortality [Odds ratio (OR) 0.8, <em>p</em> &lt; 0.001], with adjustment for other relevant parameters.</div></div><div><h3>Conclusions</h3><div>The Healthier-SG implementation was associated with significantly reduced HLOS and decreased in-hospital mortality during the early phase of Healthier-SG, even though the expected shift away of the chronic disease conditions from acute hospitals was not seen yet.</div></div>","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 1","pages":"Article 100968"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143160789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How long has the patient been like this?","authors":"Marianna Evangelia Kapsetaki","doi":"10.1016/j.hlpt.2025.100983","DOIUrl":"10.1016/j.hlpt.2025.100983","url":null,"abstract":"","PeriodicalId":48672,"journal":{"name":"Health Policy and Technology","volume":"14 2","pages":"Article 100983"},"PeriodicalIF":3.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}